World Health Organization • SEARO/CDS/IVD • 31 August 2021 ExpAnDED pROgRAmmE On ImmunIzAtIOn (EpI) Table 1: Basic information 2020 Table 2: Immunization schedule, 2020 Table 3: Immunization system highlights EPI HISTORY • EPI started in 1978 • EPI re-structured in March 2000 • DTP-HepB vaccine introduced in 2007 • DTP-Hib-HepB)vaccine introduced in 2012 • MR vaccine introduced in Feb 2016 • Second dose of MR introduced in Feb 2016 • HepB birth dose introduced in Feb 2016 • DPT/DT vaccine (booster dose) introduced in Feb 2016 • IPV introduced in Feb 2016 • tOPV to bOPV switched on 18 April 2016 • Rotavirus vaccine introduced in Dec 2019 Source: cMYP 2016-2020 and EPI/MOH Disclaimer: The boundaries and names shown and the designations used on all the maps do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. TIMOR LESTE Total population 1 1,299,412 Live births 1 33,333 Children <1 year 1 31,905 Children <5 years 1 478,804 Children <15 years 1 160,621 Pregnant women 1 41,196 WCBA1 (15-49 years) 322,969 Neonatal mortality rate 2 19.6 (per 1,000 LB) Infant mortality rate 2 38.1 (per 1,000 LB) Under-five mortality rate 2 44.2 (per 1,000 LB) Maternal mortality ratio 2 142 (per 100,000 LB) Division/Province/State/Region 13 Municipality 13 Postos/Sub-district 65 Sucos/Village 452 Population density 1 (per sq. km) 87 Population living in urban areas 2 35.80% Population using at least basic drinking- water services 2 86% Population using at least basic sanitation services 2 57% Total expenditure on health as % of GDP 2 1.48% Births attended by skilled health personnel 57% Neonates protected at birth against NT 2 83% 1 SEAR annual EPI reporting form, 2020 2 WHO, Global Health Observatory (GHO) data http://apps.who. int/gho/data accessed on 01 August 2021 Figure 1: National immunization coverage, 1980-2020 Source: WHO and UNICEF estimates of immunization coverage Vaccine Age of administration BCG Birth HepB Birth DTP-Hib-HepB 6 weeks, 10 weeks and 14 weeks OPV Birth, 6 weeks, 10 weeks and 14 weeks IPV 14 weeks MR 9 months and 18 months Td Females 15 to 49 years (1 st pregnancy contact, +1 months, +6 months, +1 year, +1 year) DT 6 years DTP 18 months Rotavirus 6 weeks, 10 weeks and 14 weeks Vitamin A 6 -36 months (with 6 months interval) Source: WHO/UNICEF JRF, 2020 cMYP for immunization 2016-2020 NITAG-TL fully functional Spending on vaccines financed by the government 75% Spending on routine immunization programme financed by the government 75% Updated micro-plans that include activities to improve immunization coverage 13 districts (100%) National policy for health care waste management including waste from immunization activities in place National system to monitor AEFI in place Most recent EPI CES EPI Coverage survey 2018 >80% coverage for DTP-Hib-HepB3 13 districts (100%) >90% coverage for MCV1 13 districts (100%) >90% coverage for MCV1 None 0% >10% drop-out rate for DTP-Hib- HepB1 to DTP-Hib-HepB3 2 districts 15% Source: WHO/UNICEF JRF, 2020 FACTSHEET 2021
This document is posted to help you gain knowledge. Please leave a comment to let me know what you think about it! Share it to your friends and learn new things together.
Transcript
World Health Organization • SEARO/CDS/IVD • 31 August 2021
ExpAnDED pROgRAmmE On ImmunIzAtIOn (EpI)
Table 1: Basic information 2020 Table 2: Immunization schedule, 2020
1 Number of discarded AFP cases per 100,000 children under 15 years of age. 2 Percent with 2 specimens, 24 hours apart and within 14 days of paralysis onset.3 Results reported within 14 days of sample received at laboratory.
1 WHO and UNICEF estimates of immunization coverage 1 WHO and UNICEF estimates of immunization coverage2 WHO vaccine-preventable diseases: monitoring system 2020
Figure 12: 2019
Figure 15: 2020
<80% 80%-89% 90%-94% >95%
year Antigen Geographic coverage Target group Target coverage %
2003 M nationwide 9to59months 128,318 99%
2006 M nationwide 6monthsto14years 390,687 40%
2009 M nationwide 9to59months 167,136 76%
2011 M nationwide 6monthsto14years 494,427 92%
2015 MR nationwide 6monthsto14years 501,832 97%
2018 MR nationwide 6to59months 142,935 110%
Figure 13: 2020
Figure 14: 2019
Figure 16: Immunity against measles - immunity profile by age in 2020*
Figure 18: confirmed measles cases* by month 2018-2020
Figure 17: Immunity against rubella through vaccination - immunity profile by age in 2020*
Figure 19: confirmed rubella cases* by month 2018-2020
*Modeled using WHO and UNICEF estimates and JRF (multiple years) and does not include immunity due to natural infection
*Includes laboratory confirmed, epidemiologically linked and clinically compatible casesSource: SEAR measles case-based data
*Includes laboratory confirmed and epidemiologically linked cases Source: SEAR measles case-based data
*Modeled using MSP tool ver 2
Vaccines ProtectSUSTAIN. ACCELERATE. INNOVATE.
Figure 20: Vaccination status of confirmed (laboratory, Epi linked and clinically compatible) measles cases, by age in 2019 and 2020
Figure 21: Vaccination status of confirmed (laboratory and Epi linked) rubella cases, by age in 2019 and 2020
Table 8: summary of measles surveillance indicators, 2018-2020 Figure 22: Network of Who supported surveillance and immunization medical officers and laboratories
Source: SEAR measles case-based data
Source: SEAR Annual EPI Reporting Form (multiple years) ND=No data
Percentage of IgM results reported to the national publichealthauthoritiesby the laboratorywithin4daysof receiptofspecimens
≥80% 44 85 ND
GenotypesdetectedMeasles ND ND NDRubella ND ND ND
Forcontactorfeedback:Expanded Programme on ImmunizationMinistryofHealth,Dilli,TimorLesteTel:+670-77351964,Fax:+670-7250097Email:[email protected],www.moh.gov.tl
Immunization and Vaccine Development (IVD)WHO-SEARO,IPEstate,MGMarg,NewDelhi110002,IndiaTel:+911123370804,Fax:+911123370251Email:[email protected]/southeastasia/health-topics/immunization